Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a simple heart rate drug prevent Surgery-Related heart attacks?

NCT ID NCT07168421

First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 39 times

Summary

This study tests whether the drug landiolol can safely keep heart rate below 90 beats per minute during major surgery in 114 patients at risk for heart problems. The goal is to see if this approach is feasible and might reduce heart injury after surgery. Participants receive landiolol continuously during and after surgery, with the dose adjusted to maintain the target heart rate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR (CV) RISK are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bern University Hospital, Freiburgstrasse

    RECRUITING

    Bern, 3010, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Landiolol (a short-acting beta-blocker given intravenously)

What this could lead to

If successful, this could show that controlling heart rate during surgery is feasible and may reduce heart damage in high-risk patients.

What could go wrong

This is a small feasibility trial, not designed to prove the drug prevents heart injury. The heart rate target may not be achievable or may cause side effects like low blood pressure.

Conditions

The condition(s) this trial relates to.

primary dysautonomia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.